Share This Page
Drugs in ATC Class L01EJ
✉ Email this page to a colleague
Drugs in ATC Class: L01EJ - Janus-associated kinase (JAK) inhibitors
| Tradename | Generic Name |
|---|---|
| INREBIC | fedratinib hydrochloride |
| JAKAFI | ruxolitinib phosphate |
| LEQSELVI | deuruxolitinib phosphate |
| OJJAARA | momelotinib dihydrochloride |
| OPZELURA | ruxolitinib phosphate |
| VONJO | pacritinib citrate |
| >Tradename | >Generic Name |
Showing 1 to 6 of 6 entries
L01EJ Market Analysis and Financial Projection
The Janus-associated kinase (JAK) inhibitors market, classified under ATC code L01EJ, is experiencing rapid growth driven by advancements in targeted therapies, increasing autoimmune disease prevalence, and strategic intellectual property (IP) expansions. Here’s a detailed breakdown of the market dynamics and patent landscape:
Market Overview and Growth Projections
- Valuation: The market is projected to grow from $20.19 billion in 2024 to $47.82 billion by 2029, at a 19.1% CAGR[1][6].
- Drivers:
- Rising autoimmune disorders (e.g., 8 million+ psoriasis cases in the U.S. and 125 million globally) and demand for targeted therapies[1][12].
- Innovations in selective JAK inhibitors (e.g., improved safety profiles) and combination therapies[12].
- Regulatory approvals for indications like myelofibrosis, rheumatoid arthritis, and alopecia[1][7].
Key Therapies and ATC Classifications
- L01EJ Drugs: Includes ruxolitinib (L01EJ01), fedratinib (L01EJ02), and pacritinib (L01EJ03), primarily used for myelofibrosis[13].
- Consumption Trends: In Norway, JAK inhibitors accounted for 9% of oral protein kinase inhibitor use (measured in DDD/1000 inhabitants/day)[3].
Patent Landscape and Innovations
Leading Patents and IP Strategies
-
Aclaris Therapeutics:
- Patents cover baricitinib, ruxolitinib, and tofacitinib for hair loss disorders (e.g., alopecia areata), with claims extending to 2031[7][15].
- Expanded IP portfolios include oral and topical formulations for selective JAK 1/3 inhibition[2][15].
-
Sun Pharmaceutical:
- Granted a patent for a structural JAK1/JAK2 inhibitor compound with deuterium modifications for enhanced stability[4].
-
Biora Therapeutics:
- Patented NaviCap platform for localized JAK inhibitor delivery in gastrointestinal disorders, reducing systemic toxicity[14].
Regulatory and Safety Considerations
- Safety Risks: Thrombosis, infections, and blood cell changes necessitate stringent monitoring[12].
- Regulatory Hurdles: Delays in approvals due to safety reviews (e.g., FDA’s scrutiny of JAK inhibitors post-COVID-19)[12].
Market Trends and Competitive Strategies
- Selective Inhibitors: Development of JAK1/JAK3-selective drugs (e.g., Aclaris’ ATI-501/502) to minimize off-target effects[2][12].
- Combination Therapies: Pairing JAK inhibitors with biologics or small molecules to enhance efficacy[12].
- Geographic Expansion: Emerging markets in Asia-Pacific and Africa due to rising autoimmune disease burdens[12].
Future Outlook
- Pipeline Drugs: Momelotinib (JAK1/2 inhibitor for myelofibrosis) and BT-600 (Biora’s GI-targeted therapy) highlight diversification[9][14].
- Patent Cliffs: Incyte’s Jakafi (ruxolitinib) faces exclusivity loss by 2025, prompting launches of new therapies like ulcerative colitis drug povorcitinib[16].
- AI Integration: Use of machine learning for drug discovery and dose optimization[12].
Challenges and Opportunities
| Challenges | Opportunities |
|---|---|
| Safety concerns and monitoring | Expanded use in dermatology (e.g., vitiligo) |
| Generic competition post-2025 | Growth in biologic/JAK inhibitor combos |
| Regulatory complexity | Localized delivery systems (e.g., NaviCap)[14] |
“The issuance of these patents is another successful step in developing a robust IP portfolio relating to JAK inhibition and hair loss.” – Aclaris Therapeutics[7]
The JAK inhibitor market’s trajectory underscores the interplay of clinical innovation, IP strategy, and adaptive regulatory navigation, positioning it as a cornerstone of autoimmune and oncology therapy development.
References
- https://www.researchandmarkets.com/reports/5895385/janus-kinase-jak-inhibitors-market-report
- https://aclaristherapeuticsinc.gcs-web.com/news-releases/news-release-details/aclaris-therapeutics-announces-issuance-us-patent-covering-jak
- https://www.ntnu.no/ojs/index.php/norepid/article/view/4041/3728
- https://www.pharmaceutical-technology.com/data-insights/sun-pharmaceutical-industries-gets-grant-for-hair-loss-treatment-using-jak1-jak2-inhibitor-compound/
- https://www.verifiedmarketresearch.com/product/janus-kinase-inhibitor-jak-market/
- https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report
- https://investor.aclaristx.com/news-releases/news-release-details/aclaris-therapeutics-announces-issuance-two-us-patents-covering
- https://www.rx-info.co.uk/news-views/atc-update-2021/
- https://go.drugbank.com/drugs/DB11697
- https://pubchem.ncbi.nlm.nih.gov/compound/25062766
- https://www.atccode.com/L01EJ
- https://markwideresearch.com/global-janus-kinase-inhibitor-jak-market/
- https://atcddd.fhi.no/atc_ddd_index/?code=L01EJ&showdescription=yes
- https://drug-dev.com/biora-therapeutics-announces-new-patent-for-its-navicap-targeted-oral-delivery-platform/
- https://drug-dev.com/aclaris-therapeutics-announces-the-allowance-of-a-us-patent-application-issuance-covering-hair-loss-disorders/
- https://www.fiercepharma.com/pharma/jakafis-patent-cliff-looming-incyte-looks-2025-launches-bulk-revenue-decades-end
- https://www.jpo.go.jp/e/resources/report/statusreport/2025/index.html
More… ↓
